

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human Neuropilin-2 in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody does not cross-react with recombinant rat (rr) Neuropilin-1 or rrNeuropilin-2.
Source	Monoclonal Mouse IgG _{2B} Clone # 257107
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Neuropilin-2 Arg21-Tyr855 Accession # NP_003863
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Neuropilin-2 (Npn-2) is a 120 kDa, type I transmembrane (TM) glycoprotein that is related to the semaphorin receptor now known as Neuropilin-1 (1). Npn-2 is a complex molecule with multiple splice forms. Five transmembrane forms are known, and one 62 kDa soluble form has been identified (2). Based on the originally reported precursor size of 909 amino acids (aa), the "standard" precursor in human will have a 20 aa signal sequence, an 842 aa extracellular region, a 25 aa TM segment, and a 42 aa cytoplasmic tail (1). The extracellular region contains two N-terminal CUB (C1r/Ugef/BMP-1) domains, two jellyroll-shaped coagulation factor V type C domains, and a juxtamembrane MAM (meprin/A-5 protein/tyrosine phosphatase μ) domain (1, 3). The CUB and factor V domain are involved in VEGF and semaphorin binding. The MAM domain appears necessary for signaling through plexin-1 (4). The five transmembrane isoforms all share the same CUB, factor V and MAM domains. Splicing begins at aa 809, seven amino acids after the end of the MAM domain, and it involves the end of the extracellular region, the TM segment, and the cytoplasmic domain (a total of 101 aa). Two of the four variants show a complete replacement of these 101 aa with a totally unrelated stretch of approximately 90 aa. This creates a new TM and cytoplasmic tail. These forms are called "Npn-2b" forms. Two other isoforms (plus the standard 909 aa form) retain the 101 aa stretch, and add either 17 or 22 aa to the end of the extracellular region. These forms are called "Npn-2a" forms. The isoform offered by R&D Systems is the "a" form with the 17 aa addition. This isoform shows 94% aa identity to the equivalent regions in mouse and rat Npn-2. The soluble form of Npn-2 is 555 aa in precursor length, and contains the two CUB domains plus the first 1½ factor V type C domains (1). Npn-2 binds Sema3B through F, and VEGF isoforms 165, 145, PlGF-2, and VEGF-C (5). It is known to form homodimers and heterodimers with Npn-1, and it forms receptor complexes with plexin-1 and VEGFR1 (4, 5). Npn-2 is found on a variety of cell types including neurons (motor, autonomic, sensory), vascular endothelial cells, Schwann cells and pancreatic acinar cells.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.